Mologic expands US and UK operations
Bedfordshire, UK, 1 April 2019: Mologic Ltd, a leading developer of lateral flow and rapid diagnostic technologies, services and products, today announced it has completed the latest phase of the Company’s expansion plans. Significant to this has been the opening of a US subsidiary and key appointments made at both US and UK sites. The recent developments bolster Mologic’s presence in the US and support the expansion of UK-based manufacturing facilities.
Key appointments include Steve Fletcher as President of Mologic Inc. and Chief Commercial Officer, heading the Company’s US Headquarters located just outside of Boston, MA. Steve will be working to broaden Mologic’s presence in the US, building commercial operations for strategic partnering and contract research, and developing the Company’s internal product pipeline. Steve has over 25 years’ experience in leading marketing, product and business operations for global healthcare companies including 3M, Thermo Fisher and GC America.
Mologic’s Executive team has been further strengthened with the appointments of Tim Dwyer as Chief Technology Officer (CTO) and Dr. Joseph Fitchett as Chief Medical Officer (CMO) & Head of Global Health to support the expansion of its UK facilities.
Tim recently joined Mologic as CTO to lead technical and scientific functions, and drive internal product activities. He is a Chartered Biologist and a Fellow of the Royal Society of Biology with over 19 years of experience in the design and development of diagnostic devices on multiple immunoassay platform technologies. Tim’s appointment supports the expansion of Mologic’s UK facilities which includes the consolidation the Company’s Molecular Antibody Development and Recombinant Protein Expression business units into a single specialist facility and the doubling of device manufacturing capacity.
As CMO, Joe has responsibility for strengthening the Company’s ties with the clinical community and directing its Global Health programmes. In his previous role as a Program Officer at the Bill & Melinda Gates Foundation, Joseph advanced the foundation’s bilateral partnerships with EU donors, including the manufacturing capacity of yellow fever vaccine and infectious disease surveillance and control at the Institut Pasteur in Dakar. Joseph trained in clinical medicine at Imperial College London, Guy’s and St Thomas’ Hospital, and in immunology of infectious diseases at The London School of Hygiene & Tropical Medicine.
Supporting the latest phase in expansion, Mologic has made further appointments to its US team, including Stephen Crossland as VP of Sales and Business Development, and Andrew Wheeler as US R&D Manager. Stephen has over 10 years’ experience in the sales and commercialisation of medical technologies, and will be directing commercial efforts, and identifying strategic partners for Mologic’s key focus areas. Andrew is joining the team with over 18 years’ experience in rapid diagnostics development, and will be working with Stephen to support Mologic’s new and existing US customers by providing technical expertise and support in diagnostic development.
Steve Fletcher, President, Mologic Inc. and Chief Commercial Officer said: “The opening of our US headquarters is key to expanding Mologic’s presence in North America, not only in terms of supporting new and existing contract research customers, but also in developing clinical and industry partnerships to commercialise our product pipeline. The science and technology, and diagnostic development experience that exists in Mologic is world class, so it is key we build an experienced team in the US to tell the Mologic story. We are already seeing great opportunity, which I look forward to progressing.”
Mark Davis, Mologic Co-Founder and Chief Executive Officer, commented: “Following the series of successful fundraising rounds, we continue to invest in the Mologic expert team and facilities. Opening a US office and recent UK expansion is key to delivering our ambitious growth strategy and I look forward to working with Steve, Tim, Joe and the rest of the team, in further establishing Mologic as the leading developer of lateral flow and rapid diagnostic technologies.”
To find out more about Mologic visit: https://mologic.co.uk/
Notes to Editors
Sarah Jeffery, Zyme Communications
+44 (0)7771 730919
About Mologic www.mologic.co.uk
Mologic is a leading developer of lateral flow and rapid diagnostic technologies, services and products. We work with companies, researchers and clinicians to help them deliver fast, reliable and accurate diagnosis at the point-of-care. Our founder, Paul Davis, was the originator of the Clearblue pregnancy test that was launched in 1988 as the world’s first commercial application of lateral flow technology. The creativity, insight and knowledge that led to that ground-breaking invention has guided Mologic since our formation in 2003.
Mologic offers world-leading scientific research expertise for contract research and development in human healthcare, agriculture and aquaculture alongside a portfolio of device and reagent products for clinical and commercial applications. We also help companies to scale-up manufacturing from initial prototyping through low to mid-scale production. Mologic’s science has broad application across markets and disease states where rapid, accurate point-of-care testing can help make a difference in patient care and patient outcomes. The result has been an internal product pipeline of rapid point-of-care diagnostics that include respiratory disease, infection / infectious disease and women’s health.
Mologic is actively seeking partners for commercialisation of its product pipeline and those looking to create, scale-up or manufacture a new point-of-care diagnostic.
Mologic is headquartered in Bedford in the United Kingdom and has a US subsidiary in the greater Boston area, MA, USA.